FibroBiologics, Inc. Common Stock (FBLG) Revenue History
Annual and quarterly revenue from 2020 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
FBLG Revenue Growth
FBLG Revenue Analysis (2020–2025)
As of May 8, 2026, FibroBiologics, Inc. Common Stock (FBLG) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, FBLG's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including MESO (+191.4% YoY), NKTR (-43.9% YoY), and MDXG (+10.5% YoY). Compare FBLG vs MESO →
FBLG Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FBLGCurrent | $0 | - | - | - | |
 MESO | $17M | +191.4% | -11.8% | -363.1% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 MDXG | $419M | +10.5% | +11.0% | 15.3% | |
 RGEN | $738M | +17.4% | +15.0% | 8.1% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% |
FBLG Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-832,000 | - | $-16,649,000 | - |
| 2024 | $0 | - | $0 | - | $-13,737,000 | - |
| 2023 | $0 | - | $0 | - | $-8,889,000 | - |
| 2022 | $0 | - | $0 | - | $-4,467,000 | - |
| 2021 | $0 | - | $0 | - | $-1,578,000 | - |
| 2020 | $0 | - | $0 | - | $-1,169,000 | - |
See FBLG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FBLG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FBLG vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFBLG — Frequently Asked Questions
Quick answers to the most common questions about buying FBLG stock.
Is FBLG's revenue growth accelerating or slowing?
FBLG TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is FBLG's long-term revenue growth rate?
FibroBiologics, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is FBLG's revenue distributed by segment?
FBLG reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.